DME

According to the company, if approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME.

Retina experts deliberate on the role of fluorescein angiography in AMD and discuss initiation of anticomplement therapy for geographic atrophy in conjunction with anti-VEGF therapy for neovascular AMD.

Roger Goldberg, MD, presents a case of a patient showing signs of geographic atrophy who subsequently develops nAMD and highlights the favorable outcomes achieved through anti-VEGF therapy.

The expert panel discusses what constitutes treatment failure in anti-VEGF therapy for nAMD and examines how various treatments may yield varying results in managing PED.

Adrienne Scott, MD, presents a case of neovascular AMD with PED in a patient who experiences a stroke while on anti-VEGF therapy.

Expert retina specialists deliberate on their approach to treating DME, emphasizing their primary treatment choice and cases where they would use PRP laser therapy and steroids alongside anti-VEGF treatments.

Carl Danzig, MD, presents a case involving a patient with both DME and PDR, showcasing the impressive anatomic improvement achieved by treating with a dual anti-VEGF and Ang2 inhibitor.

Rishi Singh, MD, discusses the criteria for identifying patients who would benefit from biosimilar therapy.

Rishi Singh, MD, presents a case of neovascular age-related macular degeneration and diabetic macular edema demonstrating how the use of ranibizumab biosimilars can yield remarkable anatomical improvements comparable to those expected with reference biologics.

Rishi Singh, MD, provides an overview of biosimilars in the context of retinal diseases and discusses their significance within the healthcare system.

The Kingfisher Study found that the visual outcomes after 1 year of brolucizumab, 6 mg, (Beovu, Novartis) in participants with diabetic macular edema (DME) did not differ significantly from those obtained with aflibercept

Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint in the clinical trial.

Previously, the EMA had approved Eylea in a dosage of 2 mg. After considering the EMA’s recommendation, the European Commission will decide whether to issue final approval of the drug.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

Resolution of macular leakage is an early biomarker of vascular stability.

In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.

According to the company, 4D-150 comprises its customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

The trial is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects with cystoid macular edema.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

At the 2023 ASRS meeting in Seattle, Washington, Diana Do, MD joined our team to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema.

The company also provided an update on tarcocimab development program for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg Injection.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”